
FDA Deploys Generative AI Agency-Wide by June 30
The FDA is accelerating generative AI adoption across all centers to enhance scientific reviews for drugs, devices, and biologics. This analysis covers the timeline, stakeholder impacts, governance challenges, and why it sets a precedent for federal AI. Discover the implications now.










